GUANGZHOU INNOGEN PHARMACE-H signed an agreement valued at over $1.0B with Arcera Life Sciences on Thursday morning to commercialize its GLP-1 receptor agonist drugs. The licensing deal expands the China-based developer's reach for its type 2 diabetes treatments into emerging international markets. The partnership provides the Abu Dhabi-headquartered firm exclusive rights to commercialize Efsubaglutide Alfa across selected territories.
Innogen Signs Billion Dollar Diabetes Deal
Guangzhou Innogen signed a licensing agreement worth over one billion dollars with Arcera Life Sciences. The deal covers diabetes drugs across multiple global regions.
Xurve View
Insights:
Xurve View






